Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.
B.1.351
COVID-19
RDV
SARS-CoV-2
monoclonal antibodies
remdesivir
therapy
variants
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
27 07 2021
27 07 2021
Historique:
received:
27
01
2021
revised:
22
04
2021
accepted:
02
07
2021
pubmed:
22
7
2021
medline:
12
8
2021
entrez:
21
7
2021
Statut:
ppublish
Résumé
Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants.
Identifiants
pubmed: 34289384
pii: S2211-1247(21)00867-6
doi: 10.1016/j.celrep.2021.109450
pmc: PMC8270748
mid: NIHMS1728470
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antiviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109450Subventions
Organisme : NIAID NIH HHS
ID : F32 AI152296
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016086
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132178
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007151
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.Y.F., E.B., D.P.P., and T.C. are employed by Gilead Sciences Inc.
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Antiviral Res. 2019 Sep;169:104541
pubmed: 31233808
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
N Engl J Med. 2021 Mar 11;384(10):905-914
pubmed: 33356051
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2021 Aug 13;373(6556):
pubmed: 34210892
Cell Host Microbe. 2020 Sep 9;28(3):486-496.e6
pubmed: 32738193
Cell. 2020 Nov 12;183(4):1070-1085.e12
pubmed: 33031744
Antiviral Res. 2021 Apr;188:105033
pubmed: 33549572
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
Am J Respir Cell Mol Biol. 2011 May;44(5):725-38
pubmed: 21531958
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
PLoS One. 2015 Jun 26;10(6):e0131451
pubmed: 26115403
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33211088
Nature. 2020 Oct;586(7830):560-566
pubmed: 32854108
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
PLoS Pathog. 2018 Jan 2;14(1):e1006810
pubmed: 29293660